Curis, Inc.

CRIS

US2312693094

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
14.85 ^USD	+3.77%		+1.99%	+16.47%

Feb. 09	HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating	MT
Feb. 08	Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Curis, Inc.(NasdaqGM:CRIS) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Curis, Inc.

HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating	Feb. 09	MT
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Transcript : Curis, Inc., Q4 2023 Earnings Call, Feb 08, 2024	Feb. 08
Earnings Flash (CRIS) CURIS Reports Q4 Revenue $2.7M, vs. Street Est of $3.1M	Feb. 08	MT
Curis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 08	CI
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study	Dec. 12	CI
Curis, Inc. Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma	Dec. 05	CI
Truist Starts Curis With Buy Rating	Nov. 17	MT
Transcript : Curis, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (CRIS) CURIS Posts Q3 Revenue $2.8M, vs. Street Est of $2.6M	Nov. 02	MT
Curis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
India's contaminated cough syrup cases	23-09-13	RE
Transcript : Curis, Inc., Q2 2023 Earnings Call, Aug 03, 2023	23-08-03
Earnings Flash (CRIS) CURIS Reports Q2 Revenue $2.2M, vs. Street Est of $2.5M	23-08-03	MT
Curis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Taseko Mines Provided Financing Update For Florence Copper	23-07-13	MT
HC Wainwright Cuts Price Target on Curis to $6 From $9, Maintains Buy Rating	23-07-07	MT
Sector Update: Health Care Stocks Softer Late Thursday	23-07-06	MT
Sector Update: Health Care Stocks Down Thursday Afternoon	23-07-06	MT
Curis Says FDA Removes Partial Clinical Hold on Emavusertib Phase 1/2 Study	23-07-06	MT
U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID	23-07-06	CI
Curis, Inc.(NasdaqCM:CRIS) dropped from Russell Microcap Index	23-06-23	CI
Curis, Inc.(NasdaqCM:CRIS) dropped from Russell Microcap Value Index	23-06-23	CI
Curis, Inc.(NasdaqCM:CRIS) dropped from Russell 3000E Value Index	23-06-23	CI
Curis, Inc.(NasdaqCM:CRIS) dropped from Russell 3000E Index	23-06-23	CI

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Curis, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.85 USD

Average target price

93 USD

Spread / Average Target

+526.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CURIS, INC.	+16.47%	87.53M
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+45.94%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research

Curis, Inc.

Equities

CRIS

US2312693094

Biotechnology & Medical Research

Curis, Inc.(NasdaqGM:CRIS) added to S&P Global BMI Index

Latest news about Curis, Inc.

Chart Curis, Inc.

Company Profile

Income Statement Evolution

Ratings for Curis, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research